Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome.

Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, Huntsman D, Camp RL, Rimm DL, American Society of Clinical Oncology, College of American Pathologists
J Clin Oncol. 2007 25 (34): 5418-25

PMID: 18048824 · DOI:10.1200/JCO.2007.12.8033

MeSH Terms (15)

Adult Aged Aged, 80 and over Biomarkers, Tumor Breast Neoplasms Cohort Studies Female Humans Immunohistochemistry Lymphatic Metastasis Middle Aged Protein Array Analysis Receptor, ErbB-2 Receptors, Estrogen Receptors, Progesterone

Connections (1)

This publication is referenced by other Labnodes entities:

Links